Țară: Irlanda
Limbă: engleză
Sursă: HPRA (Health Products Regulatory Authority)
OMEPRAZOLE
Teva Pharma B.V.
20 Milligram
Capsules Gastro-Resistant
2010-10-29
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Omeprazole Teva 20mg Gastro-resistant Capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One capsule contains 20 mg of omeprazole Excipient: sucrose. Each 20 mg capsule contains 102 to 116 mg of sucrose For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Gastro-resistant capsule, hard. Opaque yellow capsule containing off-white to cream-white spherical microgranules. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Omeprazole Teva 20 mg gastro-resistant capsules is indicated for: Adults • Treatment of duodenal ulcers • Prevention of relapse of duodenal ulcers • Treatment of gastric ulcers • Prevention of relapse of gastric ulcers • In combination with appropriate antibiotics, _Helicobacter pylori (H. pylori) _eradication in peptic ulcer disease • Treatment of NSAID-associated gastric and duodenal ulcers • Prevention of NSAID-associated gastric and duodenal ulcers in patients at risk • Treatment of reflux esophagitis • Long-term management of patients with healed reflux esophagitis • Treatment of symptomatic gastro-esophageal reflux disease • Treatment of Zollinger-Ellison syndrome Paediatric use _Children over 1 year of age and_ _10 kg_ • Treatment of reflux esophagitis • Symptomatic treatment of heartburn and acid regurgitation in gastro-esophageal reflux Disease _Children and adolescents over 4 years of age_ • In combination with antibiotics in treatment of duodenal ulcer caused by H. Pylori IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 23/03/2012_ _CRN 2112710_ _page number: 1_ 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology in adults _Treatment of duodenal ulcers_ The recommended dose in pati Citiți documentul complet